GSK outlined plans for five phase 3 studies for a gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma, after sharing early positive data. The company’s expansion to multiple phase 3 trials signals confidence in the asset’s differentiation and a strategy to establish broader clinical positioning across gynecologic oncology. The update follows an initial data package intended to support regulatory discussions and guide trial design, with GSK targeting a broader development effort rather than a single pivotal pathway. Phase 3 scaling also suggests expectations for the ADC to address multiple treatment segments. For the ADC landscape, the move highlights how licensed assets can rapidly move into late-stage programs once early signals are strong enough to justify broad phase 3 investment. Clinicians should watch how GSK sequences these phase 3 studies around current standards of care in ovarian, endometrial, and other gynecologic indications.